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Sara Rojas,a Paul S. Wheatley,b Elsa Quartapelle-Procopio,a Barbara Gil,c
Bartosz Marszalek,c Russell E. Morris*b and Elisa Barea*aThe metal–organic framework CPO-27-Ni is presented as a proof-
of-concept model for the incorporation and release of two non-
conventional anticancer drugs: [Ru(p-cymene)Cl2(pta)] (RAPTA-C)
and NO.
Nowadays, one of the most important challenges in our society
concerns the development of a more effective cancer treatment
with reduced secondary effects. Indeed, the effectiveness of
drugs in cancer therapy is mainly limited by their inadequate
transport within the body and unspecific delivery to the cancer
cells. Tumors have tortuous and defective vasculatures, with
substantial heterogeneity, and, therefore, the net effects are
both an increased flow resistance and hypoxia, which are
major obstacles in cancer therapy.1
In this regard, metal–organic frameworks (MOFs),2 which
are a new class of synthetic, porous materials, with exception-
ally high adsorption performances, have recently been studied
as selective drug carriers.3 It is noteworthy that some of these
materials exhibit a dual hydrophilic/hydrophobic pore struc-
ture, as well as an unusually high concentration of exposed
coordinatively unsaturated metal sites, which make them suit-
able as multicarrier delivering agents. In this regard, the simul-
taneous adsorption and delivery of a wide range of probe
molecules, such as bioactive gases (e.g. NO and CO)4 or small
organic drugs (e.g. busulfan and cidofovir),5 might be possible.
It has been proven that nitric oxide (NO) is an impor-
tant species involved in many biological processes.6Indeed, it mediates a number of vital functions, including
vasodilatation7 and re-epithelization.8 The accumulation of
high concentrations of nitric oxide in tumours offers the
possibility to increase cancer cells' sensitivity to chemo-
and radiotherapy or even to suddenly induce their apopto-
sis.9 Remarkably, recent studies described the use of NO
to enhance cisplatin cytotoxicity in V79 lung fibroblast
cells taking advantage from the direct sensitizing of
tumour cells.10
A number of porous materials have been described as
delivering agents for exogenous NO. This is the case for some
zeolites11 and the [M2(C8H2O6)(H2O)2]·(H2O)8 (CPO-27-M)
coordination polymer series (M = Ni, Zn, Mg, Mn, Fe, and
Co; C8H2O6 = 2,5-dihydroxyterephthalic acid). Regarding the
latter, the first highly crystalline member of the series based
on Co2+ cations (CPO-27-Co) was synthesized by Dietzel and
co-workers in 2005.12 Since this initial synthesis, several ana-
logues have been produced containing Ni2+,13 Zn2+,14 Mg2+,15
Mn2+16 and very recently Fe2+.17 Particularly, the Ni2+ deriva-
tive presents a high adsorption–delivery capacity for NO.18
The presence of coordinatively unsaturated metal sites (CUSs)
on the pore walls has a clear effect on the NO adsorption and
release processes. Indeed, during the adsorption process, an
adduct Ni–NO is formed which makes possible the incorpora-
tion and posterior water-triggered release of up to 7 mmol of
NO per g of material. Furthermore, it has been shown that
CPO-27-Ni shows a reasonable balance between stability and
solubility in bovine serum after an extended period, which is
a key issue in biological applications.19
Therefore, taking into account the exceptional reversibility
of the NO adsorption in CPO-27-Ni and its stability in biologi-
cal conditions, we have studied whether this material can act
as a vehicle for multiple drugs, namely, [Ru(p-cymene)Cl2(pta)]
(pta = 1,3,5-triaza-7-phosphaadamantane) (RAPTA-C) and NO.
This organometallic ruthenium(II) arene complex has been cho-
sen as it is a non-conventional metallodrug showing significant
in vivo antitumor activity towards lung metastases in mice.20yal Society of Chemistry 2013
Fig. 2 a) N2 (77 K) and b) NO (298 K) adsorption isotherms for activated CPO-27-
Ni (green squares) and the loaded CPO-27-Ni@RAPTA-C derivative (blue triangles).
Empty symbols denote desorption.
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View Article OnlineIn addition, some of us have previously reported that the
incorporation/release of RAPTA-C in the highly porous and robust
[Ni8(OH)4(OH2)2(4,4′-(buta-1,3-diyne-1,4-diyl)bispyrazolato)6]n MOF
is possible.21 In this communication, we report on the incorpora-
tion of the non-conventional RAPTA-C metallodrug into the free
porous space of CPO-27-Ni and the subsequent uptaking of NO
(Fig. 1). Then, the release of the loaded bioactive molecules in
SBF has also been successfully achieved. The results are a proof
of concept of the possibility to load and deliver multiple drugs in
MOFs for the development of synergic anticancer therapies with
enhanced effectiveness.
Samples of CPO-27-Ni13 and RAPTA-C22 were prepared as
described in the literature (for experimental details, see the
ESI†). Thermal activation of CPO-27-Ni at 423 K removes the
water guest molecules, leaving open metal sites ready for NO
adsorption. It has been proven that the activated CPO-27-Ni
possesses remarkably high chemical stability, which is exem-
plified by its unchanged powder X-ray diffraction (XRPD)
pattern upon stirring for 72 h in anhydrous methanol, tetra-
hydrofuran and dichloromethane (Fig. S1†). This property
let us perform the incorporation of RAPTA-C into the porous
matrix by suspending it in an 80% saturated solution of
RAPTA-C. The loading of the drug to give CPO-27-Ni@RAPTA
was preferentially achieved in CH2Cl2 as this solvent led to
the highest uptake accounting for ~4 RAPTA-C molecules
per unit cell as calculated using elemental analysis and
UV–vis (see ESI†). This result is probably due to the major
concentration of RAPTA-C in the impregnating solution as
the solubility of RAPTA-C in the apolar CH2Cl2 is signifi-
cantly higher than in MeOH or tetrahydrofuran. XRPD of
the CPO-27-Ni@RAPTA system reveals that the crystallinity of
the original porous matrix is retained (Fig. S2†), indicating that
the porous matrix has not changed during the loading process.
Furthermore, the actual incorporation of the Ru-metallodrug is
proven by i) the dramatic reduction of the adsorption capacity
of the MOF (SBET drops from 720 m2 g−1 for the original mate-
rial to 45 m2 g−1 after RAPTA-C loading) (Fig. 2a); ii) the pres-
ence of the main peaks of the pure RAPTA-C in the IRFig. 1 Thermal activation of the CPO-27-Ni metal–organic framework to remove
the solvent guest molecules and the subsequent loading with NO and RAPTA-C.
Color code: H: white, C: grey, O: red, N: blue, Ni: dark green, Ru: light orange, P:
orange, Cl: bright green.
This journal is © The Royal Society of Chemistry 2013spectrum of CPO-27-Ni@RAPTA (Fig. S3†); and iii) the increase
of the thermal stability of CPO-27-Ni@RAPTA compared to the
unloaded CPO-27-Ni material, together with a less steep weight
loss for the decomposition process (Fig. S4†).
Once the porous matrix was loaded with the non-
conventional metallodrug RAPTA-C, gravimetric NO adsorp-
tion measurements at room temperature revealed that
CPO-27-Ni@RAPTA adsorbs 6.0 mmol of NO per g of acti-
vated material (Fig. 2b). This value is very close to the one
obtained for the original CPO-27-Ni (7 mmol NO per g of
MOF), which means that the presence of RAPTA-C in the
cavities does not hamper the access of NO to the open
metal sites. The adsorbed NO accounts for ~1 NO mole-
cule per CUS, although there will also be a small amount
of weakly physisorbed NO interacting with the pore sur-
face. Moreover, the shape of the NO isotherms is
maintained showing a hysteresis loop typical of those
materials in which the NO molecule strongly binds the
metal atom. This fact supports that the main NO incorpo-
ration mechanism (chemisorption) is independent from
that of the RAPTA-C adsorption process (physisorption).
The presence of NO in the porous matrix was confirmed
with IR spectroscopy (Fig. S5†). The stretching band at
1839 cm−1 is somewhat less intense than the one found
for the original CPO-27-Ni material loaded with NO, which
further supports the lower amount of adsorbed NO inCrystEngComm, 2013, 15, 9364–9367 | 9365
Fig. 4 Desorption kinetics profile of RAPTA-C in SBF at 310 K from the original
CPO-27-Ni porous matrix and the one loaded with NO. Both materials behave in a
similar manner realising the 25% of RAPTA-C in 2 h.
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View Article Onlinecomparison with the original porous matrix, as a result of the
space occupied by the RAPTA-C molecules inside the cavities.
Similar shape of the band and its position confirms adsorp-
tion on the CUS sites inside the channels of the material and
not only physisorption at the external surface.
As previously reported,18 water molecules can trigger the
delivery of coordinated NO, replacing them from the open
metal sites. Fig. 3 shows the releasing profile of NO for
CPO-27-Ni@NO and CPO-27-Ni@RAPTA-C@NO when exposed
to a wet gas containing 11% of relative humidity. As previously
reported for CPO-27-Ni, CPO-27-Ni@RAPTA also releases
physisorbed NO very quickly as a sharp spike appearing within
the first few minutes of the kinetic of release (Fig. 3). However,
the release of the chemisorbed NO is much slower and seems
to be affected by RAPTA-C inclusion into the pores. Indeed,
CPO-27-Ni@RAPTA-C@NO releases NO significantly faster
(half life of release = 23 min) than unloaded CPO-27-Ni@NO
(half life of release = 40 min), as appreciated by a steeper drop
of NO concentration for the former material. The total amount
of stored NO is completely released in both cases. Although in
the case of CPO-27-Ni@RAPTA-C@NO, the major quantity of
stored gas is recovered within 2 hours, after 12 hours, a signifi-
cant amount of NO is still being released. These results indi-
cate that the incorporation of RAPTA-C into the pores of the
framework does not significantly affect the NO adsorption/
desorption processes. Nevertheless, we can appreciate a
change in the desorption kinetics, which is faster in the case
of the RAPTA-C loaded material.
The further step has been the study of the RAPTA-C
delivery process from the CPO-27-Ni@RAPTA-C@NO loaded
material and the evaluation of the effects of NO incorpo-
ration. For this purpose, we suspended two samples of
CPO-27-Ni@RAPTA-C, untreated and NO loaded, into a
simulated body fluid (SBF) at 310 K in order to compare
RAPTA-C desorption kinetics profiles. As depicted in
Fig. 4, there are no significant differences for the NO
loaded and unloaded samples, since both samples release
about 25% loaded RAPTA-C within 2 h. This behaviour isFig. 3 Delivery of NO on contact with wet gas (11% relative humidity), as
measured by chemiluminescence. The materials are still releasing NO at and beyond
12 h under these conditions.
9366 | CrystEngComm, 2013, 15, 9364–9367reasonable as no interactions between adsorbed RAPTA-C
and NO take place. Indeed, it is known that the delivery
rate of NO from CPO-27-Ni is increased markedly in phys-
iological solutions with the half-life of delivery being
reduced from several hours for flowing gas to a few
minutes in contact with PBS.18 Then, considering that the
NO release from CPO-27-Ni@RAPTA@NO into SBF is
nearly instantaneous, the porous matrix becomes essen-
tially identical to the unloaded CPO-27-Ni@RAPTA, which
further supports the results. It should be noted that the
prompt release of NO may have a beneficial impact in
biological applications due to the vasodilation properties
of this signalling molecule, which may help the penetra-
tion of RAPTA-C into the cancer cells.Conclusions
In this study, we proved that the concomitant adsorption of
nitric oxide and RAPTA-C into the pores of CPO-27-Ni mate-
rial is feasible. The adsorption capacity for both species is
basically unaffected by the presence of each other. This is
attributable to the different interactions taking place between
the framework walls and the adsorbate of interest: NO
directly interacts with the Ni open metal sites (chemisorp-
tion) while RAPTA-C is only physisorbed into the pores. On
the other hand, the release of the trapped Ru-metallodrug
into SBF does not depend on the previous loading of NO into
the framework, substantially, because of the immediate
release of NO in an aqueous medium. However, the kinetics
of NO desorption in the presence of a humid flowing gas is
significantly faster for the CPO-27-Ni@RAPTA-C than for the
original CPO-27-Ni.
The investigated system must be considered as a proof of
concept of the feasibility of the concurrent adsorption of bio-
active molecules into the metal–organic frameworks. Further
investigation is envisaged for the development of novel sys-
tems in which the concomitant incorporation of two (or more)
bioactive species results in the neat improvement of theThis journal is © The Royal Society of Chemistry 2013
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View Article Onlinedelivery performances. It should be noted that the exploita-
tion of the synergic effect of multiple drugs may lead to
advanced combined therapies.
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